Abstract:Ovarian carcinosarcoma (OCS) accounts for high mortality and lacks effective therapeutic methods. So far, we lack reliable biomarkers capable of predicting the risk of aggressive course of the disease. Programmed death ligand-1 (PD-L1) is expressed in various tumors, and antibodies targeting its receptor programmed cell death 1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the expression of PD-L1 and intratumoral CD8+ T lymphocytes by immunohistochemistry from 19 OCS patients who underwent primary surgery at Fudan University Shanghai Cancer Center. The correlations between PD-L1 expression and CD8+ T lymphocytes as well as the patients' clinicopathologic characteristics were integrated and statistically analyzed. PD-L1-positive expression was observed in 52.6% of intraepithelial tissues and 47.4% of mesenchymal tissues (p = 0.370). Meanwhile, intraepithelial and mesenchymal CD8+ T lymphocytes were positive in 36.8% and 84.2% of OCS, respectively (p = 0.628). A significantly negative correlation was found between mesenchymal CD8+ T lymphocytes and PD-L1 expression (r = -0.630, p = 0.011). Intraepithelial PD-L1-positive expression was associated only with positive ascitic fluid (p = 0.008). Mesenchymal PD-L1-positive patients had a poorer survival than those with negative expression (p = 0.036). Meanwhile, intraepithelial PD-L1-positive patients had a better survival trend than PD-L1-negative patients, though no statistical significance was found (p = 0.061). There was a better postoperative survival noted in mesenchymal CD8-positive patients (p = 0.024), and allthough a better trend of OS was observed in intraepithelial CD8-positive patients, no statistical significance was found (p = 0.382). Positive tumoral CD8+ T lymphocytes and mesenchymal PD-L1-negative expression seem to be associated with better survival in OCS. It is possible that immunotherapy targeting PD-L1 pathway could be used in OCS.

Study on pS2 Expression in Patients with Epithelial Ovarian Carcinoma and Its Clinical Significance

Expression of Sox2 in Human Ovarian Epithelial Carcinoma.

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

Stage-Specific Embryonic Antigen 4 Expression In Epithelial Ovarian Carcinoma

Expression of Octamer-4 in Serous and Mucinous Ovarian Carcinoma.

Clinical Significance and Prognostic Value of Extracellular Signal-Regulated Kinases in Epithelial Ovarian Cancer

Elevated Expressions of SHP2 and GAB2 Correlated with VEGF in Eutopic and Ectopic Endometrium of Women with Ovarian Endometriosis.

Expression and Significance of EphA2 and EphB2 in Ovarian Serous Adenocarcinoma

Role of Serine arginine protein kinase 1 and Minichromosome maintenance protein 2 in predicting epithelial ovarian cancer response to treatment and prognosis

High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer

Study on the Relationship Between pS2 Protein Expression and Adjuvant Endocrine Therapeutic Effect in Breast Cancer

[Expressions of VEGF/VEGFRs and Activation of STATs in Ovarian Carcinoma].

VEGF, VEGFRs Expressions and Activated STATs in Ovarian Epithelial Carcinoma

Correlation of P53 protein expression in epithelial ovarian and chemotherapy sensitivity

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

Relationship Between Expression of Estrogen and Progesterone Receptor and Prognosis in Patients with Serous Cystadenocarcinoma of the Ovary

Clinical Outcomes and Prognostic Factors of Patients with Epithelial Ovarian Cancer Subjected to First-Line Treatment: a Retrospective Study of 251 Cases

Expression and Clinical Significance of EGFR and Ki67 in Epithelialovarian Cancer

[Clinicopathologic Study and Immunohistochemistry Comparison of Pax2, P53 and Ki-67 in Low- and High-Grade Ovarian Serous Carcinomas].

Expression of HER-2 and TOPO- Ⅱα in Ovarian Epithelial Cancer and Its Clinical Significance

Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma